27 Sep, 10:34 - Indian

SENSEX 85938.64 (0.12)

Nifty 50 26264.95 (0.19)

Nifty Bank 54289.05 (-0.16)

Nifty IT 42841.55 (1.61)

Nifty Midcap 100 60666.7 (0.33)

Nifty Next 50 77531.4 (0.58)

Nifty Pharma 23321.6 (0.30)

Nifty Smallcap 100 19386.2 (0.65)

27 Sep, 10:34 - Global

NIKKEI 225 39572.96 (1.66)

HANG SENG 20699.23 (3.89)

S&P 5819.5 (0.05)

Login/Signup
LOGIN HERE
Cancel

Metropolis Healthcare Ltd

You are Here : Home > Markets > CompanyInformation > Board Meeting
BSE Code : 542650 | NSE Symbol : METROPOLIS | ISIN : INE112L01020 | Industry : Healthcare |


Board Meeting
Announcement Date Date Of Meeting Purpose Detail
05-Aug-2024 10-Aug-2024 Quarterly Results Metropolis Healthcare Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/08/2024 inter alia to consider and approve Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended June 30 2024 Financial Results for the quarter ended June 30, 2024 (As Per BSE Announcement Dated on: 10/08/2024)
14-May-2024 21-May-2024 Quarterly Results Metropolis Healthcare Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 21/05/2024 inter alia to consider and approve Audited Standalone & Consolidated Financial Results of the Company for the quarter and financial year ended March 31 2024 Audited Standalone and Consolidated Financial Results for the quarter and financial year ended March 31, 2024 Outcome of Board Meeting (As Per BSE Announcement Dated on 21/05/2024)
26-Jan-2024 02-Feb-2024 Quarterly Results Metropolis Healthcare Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 02/02/2024 inter alia to consider and approve Unaudited Standalone & Consolidated Financial Results of the Company for the quarter and nine months ended December 31 2023. Please find attached herewith, Unaudited Financial Results (Standalone & Consolidated) For quarter and nine months ended December 31, 2023. Please find attached herewith, Outcome of Board meeting held today i.e friday, January 01, 2024 (As per BSE Announcement Dated on 02/02/2024)
29-Oct-2023 04-Nov-2023 Quarterly Results Metropolis Healthcare Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/11/2023 inter alia to consider and approve Meeting of the Board of Directors of the Company is scheduled to be held on Saturday November 04 2023 to inter alia Consider and approve the Unaudited Standalone & Consolidated Financial Results of the Company for the quarter and half year ended September 30 2023. Consider and approve the declaration of Interim Dividend for the Financial Year 2023-24 if any. METROPOLIS HEALTHCARE LIMITED has informed BSE about Board Meeting to be held on 04 Nov 2023 to consider financial statements for the period ended September 2023. Financial results / Dividend. This is to inform you that, the Board of Directors in their meeting held today i.e 4th November, 2023, has approved the declaration of an Interim Dividend of Rs. 4 per share and has fixed Friday, 17th November, 2023 as the record date. Please find attached herewith, outcome of the Board Meeting held today i.e Saturday, 4th November, 2023 This is to inform you that, the Board of Directors in their meeting held today i.e 4th November, 2023, has approved and declared payment of an Interim dividend at the rate of Rs. 4 per share and has fixed Friday, 17th November, 2023 as the Record Date. Please find attached herewith the financial results for the quarter and half year ended September 30, 2023. This is to inform you that, the Board of Directors in their meeting held today i.e 4th November, 2023, has approved the declaration of an Interim Dividend of Rs. 4 per share and has fixed Friday, 17th November, 2023 as the record date. (As Per BSE Announcement Dated on 04.11.2023) This is to inform you that the Company on Sunday, November 05 has published an extract of Unaudited Financial Results (Standalone and Consolidated) for the quarter and half year ended September 30, 2023 as approved by the Board of Directors of the Company in their Meeting held on Saturday, November 04, 2023. Please find enclosed , the copy published in Free Press Journal (English) and Navshakti (Marathi). (As Per BSE Announcement Dated on 05.11.2023)
26-Jul-2023 02-Aug-2023 Quarterly Results Metropolis Healthcare Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 02/08/2023 ,inter alia, to consider and approve We wish to inform you that a Meeting of the Board of Directors of the Company is scheduled to be held on Wednesday, August 02, 2023, to inter alia, Consider and approve Standalone and Consolidated Unaudited Financial Results of the Company for the quarter ended June 30, 2023; Further, we also wish to inform you that in terms of the Company's Code of Conduct for Prevention of Insider Trading, the Trading Window for dealing in the securities of the Company has been closed for the Designated Persons of the Company and their immediate relatives with effect from July 01, 2023 and shall re-open 48 hours after the declaration of the Financial Results of the Company for the quarter ended June 30, 2023, as intimated to the stock exchanges vide its letter MHL/Sec&Legal/2023-24/25 dated June 29, 2023. Please find attached herewith, Unaudited Financial results (standalone and consolidated) for quarter ended June 30, 2023 This is to inform you that, the Board of Directors of the Company in their meeting held today i.e August 02, 2023, have inter alia approved few agendas, details of which are enclosed herewith. (As per BSE Announcement Dated on 02/08/2023)
20-Jun-2023 19-Jun-2023 Change in Other Executives This is to inform you that the Board of Directors of the Company at their Meeting held on Monday, June 19, 2023 have approved the appointment of Ms. Neha Shah as Interim Company Secretary & Key Managerial Personnel of the Company w.e.f. June 20,2023. Ms. Neha will continue to act as Interim Compliance officer of the Company approved by the Board in its Meeting held on December 09, 2022 (Ref No: MHL/Sec&Legal/2022-23/77) In terms of Regulation 30(5) of the Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulation, 2015, Key Managerial Personnel's ('KMP') of the Company have been authorized severally for the purpose of determining materiality of an event or information and making disclosure of the same to the Stock Exchange(s). Accordingly, Ms. Neha Shah, Interim Company Secretary & Compliance Officer of the Company has also been authorized under the aforesaid regulation.
09-May-2023 16-May-2023 Accounts Metropolis Healthcare Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 16/05/2023 inter alia to consider and approve We wish to inform you that a Meeting of the Board of Directors of the Company is scheduled to be held on Tuesday May 16 2023 to inter alia consider and approve the Audited Standalone & Consolidated Financial Results of the Company for the quarter and financial year ended March 31 2023. Further we also wish to inform you that in terms of the Companys Code of Fair Disclosure of Unpublished Price Sensitive Information the Trading Window for dealing in the securities of the Company has been closed for the Designated Persons of the Company and their immediate relatives with effect from April 01 2023 and shall reopen 48 hours after the declaration of the Financial Results of the Company for the quarter and financial year ended March 31 2023 as intimated to the stock exchanges vide its letter MHL/Sec&Legal/2022-23/98 dated March 30 2023. In continuation to our letter Ref: MHL/Sec&Legal/2023-24/13 dated May 16, 2023, it is further informed that as per the requirement of Circular No. LIST/COMP/74/2018-19 dated June 20, 2018 w.r.t. Enforcement of SEBI orders regarding Appointment of Directors by Listed Companies, we hereby affirm that Mr. Sanjay Bhatnagar (DIN: 00867848) and Mr. Vivek Gambhir (DIN: 06527810) who were re-appointed as Non-Executive Independent Directors by the Board in its Meeting held on May 16, 2023 for a second term of 5 years, subject to the approval of Shareholders, are not debarred from holding the office as Director by virtue of any SEBI order or any other such authority. You are requested to kindly take the same on record. (As Per BSE Announcement dated on 17.05.2023)
01-Apr-2023 31-Mar-2023 Others This is to inform you that the Board of Directors of the Company at their Meeting held today i.e. Friday, March 31, 2023, have approved reconstitution of Audit Committee and Risk Management Committee of the Company with effect from April 01, 2023
03-Feb-2023 10-Feb-2023 Quarterly Results Intimation of Notice of Board Meeting scheduled to be held on Friday, February 10, 2023 This is to inform you that the Board of Directors of the Company at their Meeting held today i.e. Friday, February 10, 2023 have inter-alia: i. Approved the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and nine months ended December 31, 2022 and noted the Limited Review Report The Copy of the Unaudited Standalone & Consolidated Financial Results of the Company as approved by the Board of Directors together with the Limited Review Report thereon for the quarter and nine months ended December 31, 2022 is enclosed herewith as Annexure - 1. ii. Approved and Declared payment of an Interim Dividend at the rate of Rs. 8/- (Rupees Eight Only) per Equity Share on the Face Value of Rs. 2/- (Rupees Two Only) per Equity Share for the Financial Year 2022-23. The Board has fixed Thursday, February 23, 2023, as the 'Record Date'. The Interim Dividend will be paid to the shareholders within 30 days of declaration. This is to inform you that the Board of Directors of the Company at their Meeting held today i.e. Friday, February 10, 2023 have inter-alia: i. Approved and Declared payment of an Interim Dividend at the rate of Rs. 8/- (Rupees Eight Only) per Equity Share on the Face Value of Rs. 2/- (Rupees Two Only) per Equity Share for the Financial Year 2022-23. The Board has fixed Thursday, February 23, 2023, as the 'Record Date' for the purpose of ascertaining eligibility of the shareholders for payment of Interim Dividend. The Interim Dividend will be paid to the shareholders within 30 days of declaration. (As Per BSE Announcement dated on 10.02.2023) This is to inform you that the Board of Directors at its Meeting held on Friday, February 10, 2023 has inter alia, considered and approved the amendments in the Code of Fair Disclosure of Unpublished Price Sensitive Information Policy ('Code of Fair Disclosure') of the Company. The said Code of Fair Disclosure is enclosed herewith and is also being hosted on the website of the Company, viz. www.metropolisindia.com (As Per BSE Announcement Dated on 11.02.2023)
09-Dec-2022 09-Dec-2022 Change in Other Executives This is to inform you that based on the recommendation of the Nomination & Remuneration Committee, the Board of Directors of the Company in their Meeting held today i.e. Friday, December 09, 2022, have inter-alia: Approved the appointment of Mr. Surendran Chemmenkotil as Chief Executive Officer ('CEO') of the Company w.e.f. January 02, 2023; 2. Accepted and took on record the resignation of Ms. Simmi Singh Bisht from the post of Company Secretary and Compliance Officer of the Company (Designated as Head - Legal and Secretarial) w.e.f. January 07, 2023; 3. Approved the appointment of Ms. Neha Shah, Associate Company Secretary (Membership No. ACS 51465) as an Interim Compliance Officer of the Company w.e.f. January 08, 2023.
31-Oct-2022 08-Nov-2022 Quarterly Results Metropolis Healthcare Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/11/2022 inter alia to consider and approve We wish to inform you that a Meeting of the Board of Directors of the Company is scheduled to be held on Tuesday November 08 2022 to inter alia consider and approve the Standalone and Consolidated Unaudited Financial Results of the Company for the quarter and half year ended September 30 2022. Further we wish to inform you that in terms of the Companys Code of Fair Disclosure of Unpublished Price Sensitive Information the Trading Window for dealing in the securities of the Company has been closed for Designated Persons of the Company and/or their immediate relatives with effect from October 01 2022 and shall re-open 48 hours after declaration of Financial Results of the Company for the quarter and half year ended September 30 2022. Board of Directors at their Meeting held today i.e. Tuesday, November 08, 2022, based on recommendation of the Audit Committee, have considered and approved the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and half year ended September 30, 2022 and noted the Limited Review Report issued by the Statutory Auditors of the Company thereon. The copy of Unaudited Standalone & Consolidated Financial Results of the Company as approved by the Board of Directors together with the Limited Review Report thereon for the quarter and half year ended September 30, 2022 enclosed herewith. (As Per BSE Announcement Dated on 08.11.2022) This is to inform you that the Company on Thursday, November 10, 2022, had published the extract of the Unaudited Financial Results (Standalone and Consolidated) for the quarter and half year ended September 30, 2022 as approved by the Board of Directors in their meeting held on Tuesday, November 08, 2022. Please find enclosed, the copy published in Free Press Journal (English) and Navshakti (Marathi). Kindly take the same on record. (As per BSE Announcement Dated on 10/11/2022)
04-Aug-2022 10-Aug-2022 Quarterly Results Quarterly Results Metropolis Healthcare Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/08/2022 ,inter alia, to consider and approve We wish to inform you that a meeting of the Board of Directors of the Company is scheduled to be held on Wednesday, August 10, 2022, inter alia: To consider and approve the Standalone and Consolidated Unaudited Financial Results of the Company for the quarter ended June 30, 2022. (As Per BSE Announcement dated on 03.08.2022) Dear Sir/ Madam, This is to inform you that the Board of Directors at their Meeting held today i.e. Wednesday, August 10, 2022 have considered and approved the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended June 30, 2022 and took note of the Limited Review Report issued by the Statutory Auditors of the Company thereon. The copy of Unaudited Standalone & Consolidated Financial Results of the Company as approved by the Board of Directors together with the Limited Review Report thereon for the quarter ended June 30, 2022 are enclosed as Annexure - 1. The meeting commenced at 02:00 pm and concluded at 04.25 pm. (As Per BSE Announcement dated on 10.08.2022)
12-Jul-2022 18-Jul-2022 Accounts Metropolis Healthcare Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 18/07/2022 inter alia to consider and approve the revised Audited Standalone Financial results of the Company for the Quarter and Year ended March 312022 after taking on record the amalgamation of the 8(Eight) wholly owned Subsidiary Companies with the Company. Metropolis Healthcare Limited has informed the Exchange about Board Meeting held on 18-Jul-2022 to approve Revised Audited Standalone Financial Results of the Company along with revised Audit Report thereon for the quarter and year ended March 31, 2022. (Post-Merger), on account of Merger Order issued by NCLT, Mumbai as submitted by the Company earlier via letter no. MHL/Sec&Legal/2022-23/30 approving the scheme of Amalgamation & Arrangement of Merger by Absorption of subsidiaries with the Company (As per BSE Announcement Dated on 18/07/2022) This is to inform the Exchange that the Board of Directors in their Meeting held on 18-Jul-2022 has approved amendments to ''Metropolis-Restrictive Stock Unit Plan, 2020'' (the 'MHL-RSU Plan 2020'), subject to shareholders' approval in ensuring 22nd Annual General Meeting (As Per BSE Announcement dated on 19.07.2022)
16-May-2022 24-May-2022 Accounts Metropolis Healthcare Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 24/05/2022 inter alia to consider and approve This is to inform you that a meeting of the Board of Directors of the Company (the Board) is scheduled to be held on Tuesday May 24 2022 inter-alia to consider and approve the Audited Standalone & Consolidated Financial Results of the Company for the financial year ended March 31 2022. We further wish to inform you that in terms of the Companys Code of Conduct for Prevention of Insider Trading the Trading Window for dealing in the securities of the Company has been closed with effect from April 1 2022 and shall reopen 48 hours after the declaration of the financial results by the Company. This is to inform you that the Board of Directors of the Company at their meeting held today have inter-alia: 1. Approved the Standalone and Consolidated Financial Statements of the Company for the quarter and year ended March 31, 2022. The Audited Standalone and Consolidated Financial Statements of the Company as approved together with the Auditor's Report thereon for the quarter and year ended March 31, 2022 are enclosed as Annexure 1. Further, pursuant to the provisions of Regulation 33 (3) (d) of the SEBI LODR, the declaration of Unmodified Opinion by the Managing Director of the Company, in respect of the Audited Standalone and Consolidated Financial Statements of the Company for the year ended March 31, 2022 is enclosed as Annexure 2. 2. Re - appointment of B S R & Co. LLP, Chartered Accountants (ICAI Firm No. 101248W/W-100022) as Statutory Auditor of the Company for further term of 4 Years. The details pertaining to the Statutory Auditors is enclosed as Annexure 3. (As per BSE Announcement Dated on 24/5/2022) With reference to the captioned subject, we wish to inform you that the Board of Directors of the Company at its meeting held on May 24, 2022, upon the recommendation of Nomination and Remuneration Committee, considering the talent retention measure and in order to align the employees with the long term interests of the Company, has approved the revised pool size of Restrictive Stock Units (RSUs) under the Metropolis - Restrictive Stock Unit Plan - 2020 (MHL - RSU Plan 2020/RSU Plan) by way of addition of 1,00,000 (One Lakh) RSUs, thereby the revised pool size of RSUs under the Metropolis - Restrictive Stock Unit Plan - 2020 (MHL - RSU Plan 2020) shall stand increase from 2,70,000 (Two Lakh Seventy Thousand) to 3,70,000 (Three Lakh Seventy Thousand ) RSUs and other consequential amendment to RSU plan in order to align the said plan with the applicable SEBI Regulation. (As Per BSE Announcement Dated on 25.05.2022)
03-Feb-2022 11-Feb-2022 Quarterly Results Metropolis Healthcare Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/02/2022 inter alia to consider and approve 1. Consider and approve the Unaudited Standalone & Consolidated Financial Results of the Company for the quarter and nine months ended December 31 2021. 2. Consider the proposal for declaration of an Interim Dividend for the Financial Year 2021-22 if any. i. Approved the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and nine months ended December 31, 2021 and took note of the Limited Review Report issued by the Statutory Auditors on the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and nine months ended December 31, 2021. ii. Approved and declared payment of an Interim Dividend at the rate of Rs. 8/- (Rupees Eight only) per Equity Share on the Face Value of Rs. 2/- (Rupees Two only) per Equity Share for the Financial Year 2021-22. This is to inform you that the Board of Directors of the Company at their meeting held today have inter-alia approved and declared payment of an Interim Dividend at the rate of Rs. 8/- (Rupees Eight only) per Equity Share on the Face Value of Rs. 2/- (Rupees Two only) per Equity Share for the Financial Year 2021-22. i. Approved the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and nine months ended December 31, 2021 and took note of the Limited Review Report issued by the Statutory Auditors on the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and nine months ended December 31, 2021. The copy of the Unaudited Standalone & Consolidated Financial Results of the Company as approved by the Board of Directors together with the Limited Review Report thereon for the quarter and nine months ended December 31, 2021 is enclosed as Annexure - 1 ii. Approved and declared payment of an Interim Dividend at the rate of Rs. 8/- (Rupees Eight only) per Equity Share on the Face Value of Rs. 2/- (Rupees Two only) per Equity Share for the Financial Year 2021-22. (As Per BSE Announcement Dated 11.02.2022) We refer to our letter dated February 11, 2022 submitting Unaudited Consolidated Financial Results for the quarter and nine months ended December 31, 2021, Auditors' Limited Review Report and the requisite declaration on unmodified opinion (Reference no. MHL/Sec&Legal/2021-22/71) There was a typographical error in the Limited Review Report for the quarter and nine months ended December 31, 2021 that inadvertently referred to Regulation 52(4) read with Regulation 63(2) in addition to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Please find enclosed the correct Limited Review Report for the quarter and nine months ended December 31, 2021.We further state that there is no change in the revenue, profit before tax, profit and earnings per share (EPS) numbers of the Group reported in the Unaudited Consolidated Financial Results submitted to you on February 11, 2022. (As Per BSE Announcement Dated on 12.02.2022)
1 2